|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Material 3. Study results of ARB's in patients with HF** | | | | | | |
| **Study** | **Study Size** | **Protocol** | **Primary Endpoint** | **Population** | **Clinical Outcome** | **SAE due to treatment** |
| Val-HeFT (12) | 5010 | RCT, valsartan vs placebo | All-cause mortality | Symptomatic HF, EF <40% | Reduction in HF hospitalization | Combination of ARB, ACEi and beta blocker showed increased mortality |
| CHARM- Overall (13) | 7599 | RCT, candesartan vs placebo | The primary outcome of the overall program was all-cause mortality, and for all the component trials was cardiovascular death or hospital admission for CHF. | HF with EF <40% and HF with EF >40% | Significant reduced cardiovascular deaths and hospital admissions for heart failure. | More discontinuations due to renal function, hypotension, and hyperkalemia. |
| HEAAL (18) | 3846 | High-vs low- dose losartan | The primary endpoint was death or admission for heart failure | Symptomatic HF, EF <40%, intolerance of ACE inhibitor | Losartan150 mg daily reduced the rate of death or admission for heart failure in patients with heart failure, reduced left-ventricular ejection fraction, and intolerance to ACE inhibitor | cases of renal impairment, hypotension, and hyperkalemia in the high-dose group |
| ELITE (14) | 722 | Captopril vs losartan | Tolerability measure of a persisting increase in serum creatinine of 26.5 mumol/L or more (> or = 0.3 mg/dL) on therapy | New York Heart Association (NYHA) class II-IV heart failure and ejection fractions of 40% | Losartan group experienced lower mortality rates | Higher discontinuation rate in captopril group due to cough |
| VALIANT (15) | 14,808 | Valsartan vs Captopril Vs both | All-cause Mortality | Acute myocardial infarction plus evidence of left ventricular systolic dysfunction | NS difference in mortality between Valsartan and Captopril alone group. Higher mortality in combined group. | Valsartan + captopril group had increased rates of renal impairment, hypotension, and hyperkalemia |
| ONTAR-GET (16) | 25,620 | Telmisartan, Ramipril, or both | Death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure | Coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage. | NS difference in clinical benefit derived between groups | More adverse effects in combination group |
| Heran et al. (17) | 17,900 | Systemic review of RCTs investigating ARB use | Mortality, morbidity, discontinuation due to ARB use | LVEF ≤40% | ARBs did not reduce total mortality or total morbidity | Combinations of ARBs plus ACEIs increased the risk of withdrawals due to adverse effects |

﻿CHARM, Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity; ELITE, Evaluation of Losartan in the Elderly; GFR, glomerular filtration rate; HEAAL, Heart failure Endpoint Evaluation of Angiotensin II Antagonist Losartan; ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; VALIANT, Valsartan in Acute Myocardial Infarction; Val-HeFT, Valsartan in Heart Failure. ACE, angiotensin-converting-enzyme; ARB, angiotensin receptor blocker; CHF, Chronic heart failure; CKD, chronic kidney disease; HFrEF, Heart failure with reduced ejection factor; EF, ejection fraction; RCT, randomized control trial; HF, heart failure; NS, not significant; SAE, serious adverse event; SCr, serum creatinine

1.Bart BA, Boyle A, Bank AJ, Anand I, et al.. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46:2043–2046.

2. ﻿Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–683.

3. ﻿Marenzi G, Muratori M, Cosentino ER, et al. Continuous ultrafiltration ﻿for congestive heart failure: the CUORE trial. J Card Fail. 2014;20:9–17. doi: 10.1016/j.cardfail.2013.11.004

4. ﻿Costanzo MR, Negoianu D, Jaski BE, et al. Aquapheresis versus intrave- nous diuretics and hospitalizations for heart failure. JACC Heart Fail. 2016;4:95–105.

5. Belziti CA, Bagnati R, Ledesma P, Vulcano N, Fernandez S. Worsening renal function in patients admitted with acute decompensated heart failure: incidence, risk factors and prognostic implications, Rev Esp Cardiol, 2010, vol.63 (pg. 294- 302)

6. ﻿Wilcox CS, Mitch WE, Kelly RA, Skorecki K, ET AL. Response of the kidney to furosemide, I: effects of salt intake and renal compensation. J Lab Clin Med. 1983; 102:450–458.

7. ﻿Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial. Int J Cardiol. 2013;167:151–156. doi: 10.1016/j.ijcard.2011.12.056

8. ﻿Berger AK, Duval S, Manske C, et al. RV. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J. 2007;153:1064–1073.

9. ﻿Edner M, Benson L, Dahlstrom U, Lund LH. Association between renin- angiotensin system antagonist use and mortality in heart failure with se- vere renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J. 2015;36:2318–2326. doi: 10.1093/eurheartj/ehv268

10. ﻿Gurwitz JH, Magid DJ, Smith DH, et al. Treatment effective- ness in heart failure with comorbidity: lung disease and kidney disease. J Am Geriatr Soc. 2017;65:2610–2618.

11..Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363:1419–28.

12. ﻿Anand IS, Bishu K, Rector TS, et al. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009;120:1577– 1584. doi: 10.1161/CIRCULATIONAHA.109.853648

13. ﻿Desai AS, Swedberg K, McMurray JJV, et al.; CHARM Program Investigators. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007;50:1959–1966.

14. Pitt B, Segal R, Martinez FA,. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747–752.

15. Pfeffer MA, et al. "Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both". *The New England Journal of Medicine*. 2003. 349(20):1893-1903

16. Yusuf S, et al. "Telmisartan, ramipril, or both in patients at high risk for vascular events". *The New England Journal of Medicine*. 2008. 358(15):1547-1559.

17. Heran  BS, Musini  VM, Bassett  K, Taylor  RS, Wright  JM. Angiotensin receptor blockers for heart failure. Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No.: CD003040. DOI: 10.1002/14651858.CD003040.pub2.

18. Mullens, Wilfried, Zuheir Abrahams, Gary S. Francis, et al. “Sodium Nitroprusside for Advanced Low-Output Heart Failure.” Journal of the American College of Cardiology 2008. 52 (3):200–207. https://doi.org/10.1016/j.jacc.2008.02.083.

19. Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. *Eur Heart J*. 2016;37(27):2105–2114. doi:10.1093/eurheartj/ehw132

20. Mariantonietta Cicoira, Luisa Zanolla, Andrea Rossi, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure, Journal of the American College of Cardiology, 2002,Pages 304-310,

21. Edelmann F, Wachter R, Schmidt AG, et al. Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction: The Aldo-DHF Randomized Controlled Trial. JAMA. 2013;309(8):781–791. doi:10.1001/jama.2013.905

22. ﻿Nemoto M. Experimental evaluation of the influence of complete arti- ficial circulation on renal circulation and tissue metabolism -compara- tive study of pulsatile vs nonpulsatile circulation. Ann Thorac Cardiovasc Surg. 2003;9:355–364.

23. ﻿Welp H, Rukosujew A, Tjan TD, Hoffmeier A, Kösek V, Scheld HH, Drees G. Effect of pulsatile and non-pulsatile left ventricular assist de- vices on the renin-angiotensin system in patients with end-stage heart failure. Thorac Cardiovasc Surg. 2010;58(suppl 2):S185–S188. doi: 10.1055/s-0029-1240709

24. ﻿Yancy CW, Jessup M, Bozkurt B, Butler J, et. al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:1810–1852. doi: 10.1161/CIR.0b013e31829e8807

25. Abraham W. Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: The Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Journal of Cardiac Failure 2000 vol: 6 (4) pp: 369-380

26. Bazoukis G, Letsas KP, Korantzopoulos P, et al. Impact of baseline renal function on all-cause mortality in patients who underwent cardiac resynchronization therapy: A systematic review and meta-analysis. *J Arrhythm*. 2017;33(5):417–423. doi:10.1016/j.joa.2017.04.005

27. Bristow, Michael R, Leslie A Saxon, John Boehmer, et al. 2004. “Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure.” *New England Journal of Medicine* 350 (21): 2140–50. https://doi.org/10.1056/NEJMoa032423.

28. Moss AJ, et al. "Cardiac-resynchronization therapy for the prevention of heart-failure events". *The New England Journal of Medicine*. 2009. 361(14):1329-1338.